(Q38343228)

2 September 2017

title

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress (English)

1 reference

2 September 2017

0 references

9

1 reference

2 September 2017

M Ri

1

1 reference

2 September 2017

S Iida

2

1 reference

2 September 2017

T Nakashima

3

1 reference

2 September 2017

H Miyazaki

4

1 reference

2 September 2017

F Mori

5

1 reference

2 September 2017

A Ito

6

1 reference

2 September 2017

A Inagaki

7

1 reference

2 September 2017

S Kusumoto

8

1 reference

2 September 2017

H Komatsu

10

1 reference

2 September 2017

Y Shiotsu

11

1 reference

2 September 2017

R Ueda

12

1 reference

2 September 2017

publication date

17 June 2010

1 reference

2 September 2017

1 reference

2 September 2017

volume

24

1 reference

2 September 2017

issue

8

1 reference

2 September 2017

page(s)

1506-1512

1 reference

describes a project that uses

2 September 2017

KMS-11/BTZ

0 references

OPM-2/BTZ

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/leu.2010.137

0 references

cites work

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Proteasome inhibitors in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

NF-kappaB: linking inflammation and immunity to cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

The mammalian unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

21 January 2018

ER stress and diseases.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Integrated endoplasmic reticulum stress responses in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

Many facets of bortezomib resistance/susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.137

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.137

1 reference

Dimensions Publication ID

2 September 2017

1017786690

0 references

1 reference